These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 31858669)

  • 21. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels.
    Pavanello C; Pirazzi C; Bjorkman K; Sandstedt J; Tarlarini C; Mosca L; Romeo S; Calabresi L; Mancina RM
    J Clin Lipidol; 2019; 13(5):778-787.e6. PubMed ID: 31371270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.
    Carmena R; Lussier-Cacan S; Roy M; Minnich A; Lingenhel A; Kronenberg F; Davignon J
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):129-36. PubMed ID: 8548413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
    Miname MH; Bittencourt MS; Nasir K; Santos RD
    Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
    Bogsrud MP; Græsdal A; Johansen D; Langslet G; Hovland A; Arnesen KE; Mundal LJ; Retterstøl K; Wium C; Holven KB
    J Clin Lipidol; 2019; 13(2):279-286. PubMed ID: 30910667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.
    Puri R; Mehta V; Duell PB; Nair D; Mohan JC; Yusuf J; Dalal JJ; Mishra S; Kasliwal RR; Agarwal R; Mukhopadhyay S; Wardhan H; Khanna NN; Pradhan A; Mehrotra R; Kumar A; Puri S; Muruganathan A; Sattur GB; Yadav M; Singh HP; Agarwal RK; Nanda R
    J Clin Lipidol; 2020; 14(2):e1-e13. PubMed ID: 32089456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.
    Chan DC; Watts GF
    Clin Ther; 2023 Nov; 45(11):1034-1046. PubMed ID: 37524569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
    Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
    J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.
    Rehberger Likozar A; Zavrtanik M; Šebeštjen M
    Ann Med; 2020 Aug; 52(5):162-177. PubMed ID: 32453609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
    Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
    Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
    Gelsinger C; Steinhagen-Thiessen E; Kassner U
    Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
    Stefanutti C; Morozzi C; Di Giacomo S
    Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis].
    Thiery J; Seidel D
    Versicherungsmedizin; 1992 Dec; 44(6):186-92. PubMed ID: 1475888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.